CD274 and familial pancreatic carcinoma: The choice of a single anti-PD-L1 treatment for pancreatic cancer lacks immune response, so it is crucial to overcome the immunosuppressive environment of pancreatic cancer against PD-L1-targeted immunotherapy and enhance immunotherapy activity [17].